Founder and Managing Partner, Frazier Healthcare Ventures
Co-Founder, Sakti3
Founder and CEO of Brooks Bell Inc.
President & CEO, Indiana Biosciences Research Institute
Professor, Michigan State University
Founder and Managing Partner, Frazier Healthcare Ventures
VP of Research and Special Initiatives, Google
Founder and Chairman, Sycamore Networks
Cambridge, MA-based TransMolecular, a developer of cancer drugs based on a molecule derived from scorpion venom, said today it has named Robert Radie as its president and CEO. Before joining TransMolecular as a business development consultant, Radie held leadership roles at Prestwick Pharmaceuticals, Morphotek, and Vicuron Pharmaceuticals.
Xconomy Insight · Webinar
Potential cures and treatments for diseases are on the horizon for a growing number of patients, thanks to recent breakthroughs in CRISPR gene-editing technologies and in cell and gene therapy.
Sponsored · Whitepaper
Implementing electronic solutions for risk mitigation
XiltriX
Sponsored · Whitepaper
Remain compliant and ensure optimal productivity
XiltriX
Tax credits help tech innovators attract capital, fuel growth
Wisconsin Economic Development Corporation
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
